Junge Zhang
Known title: DirectorCIK: 0001790205
Junge Zhang's purchase track record
Junge Zhang has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/14/2023 | OCGN | $100K | -12.6% | -26.6% | +7.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| OCGN | ▲ Buy | Option Exercise | 66,929 | $95K | 4/1/2026 | View on chart |
| OCGN | ▲ Buy | Option Exercise | 15,000 | $8K | 4/1/2026 | View on chart |
| OCGN | ▲ Buy | Option Exercise | 112,205 | $52K | 4/1/2026 | View on chart |
| OCGN | ▲ Buy | Open Market | 200,278 | $100K | 6/14/2023 | View on chart |
| OCGN | ▲ Buy | Option Exercise | 39,000 | $20K | 3/3/2022 | View on chart |
| OCGN | ▲ Buy | Option Exercise | 49,000 | $90K | 3/3/2022 | View on chart |
| OCGN | ▼ Sell | Other | 143,820 | $398K | 11/16/2021 | View on chart |
| OCGN | ▼ Sell | Other | 1,653 | $12K | 11/16/2021 | View on chart |
| OCGN | ▼ Sell | Open Market | 150,300 | $2.6M | 11/3/2021 | View on chart |
| OCGN | ▼ Sell | Open Market | 149,700 | $2.4M | 11/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Ocugen Secures Bahamas Approval for Gene Therapy OCU400
Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.
Ocugen Secures Bahamas Approval for Gene Therapy OCU400. Ocugen received provisional approval from the Bahamas regulator to supply its gene‑therapy OCU400 for retinitis pigmentosa. The company will provide the treatment through an expanded access program and aims to treat the first patient within 90 days. The approval also grants priority designation under the Bahamas Longevity and Regenerative Therapies Act. This development may broaden global access for Ocugen’s therapy.